Follow
Neil Waters
Neil Waters
Unknown affiliation
Verified email at monash.edu
Title
Cited by
Cited by
Year
Optimal dose, timing and ratio of blood products in massive transfusion: results from a systematic review
ZK McQuilten, G Crighton, S Brunskill, JK Morison, TH Richter, N Waters, ...
Transfusion medicine reviews 32 (1), 6-15, 2018
1182018
Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use
J Shortt, MN Polizzotto, N Waters, M Borosak, M Moran, M Comande, ...
Transfusion 49 (11), 2296-2303, 2009
602009
Profiling clinical platelet and plasma use to inform blood supply and contingency planning: PUPPY, the prospective utilization of platelets and plasma study
PL Fedele, MN Polizzotto, G Grigoriadis, N Waters, M Comande, ...
Transfusion 56 (10), 2455-2465, 2016
312016
Demographic and socio-cultural correlates of medical mistrust in two Australian States: Victoria and South Australia
A Renzaho, M Polonsky, Z McQuilten, N Waters
Health & place 24, 216-224, 2013
292013
Factors leading to health care exclusion among African refugees in Australia: the case of blood donation
MJ Polonsky, AS Ferdous, AMN Renzaho, N Waters, Z McQuilten
Journal of Public Policy & Marketing 37 (2), 306-326, 2018
262018
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β‐thalassemia using time‐driven activity‐based costing
ZK McQuilten, AM Higgins, K Burns, S Chunilal, T Dunstan, HE Haysom, ...
Transfusion 59 (11), 3386-3395, 2019
162019
A time‐driven, activity‐based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major
KE Burns, HE Haysom, AM Higgins, N Waters, R Tahiri, K Rushford, ...
Transfusion Medicine 29 (1), 33-40, 2019
162019
Major haemorrhage fatalities in the Australian national coronial database
JS Gipson, EM Wood, MF Cole‐Sinclair, Z McQuilten, N Waters, ...
Emergency Medicine Australasia 30 (3), 382-388, 2018
112018
Blood donation by A frican migrants and refugees in A ustralia: the role of demographic and socio‐economic factors
Z McQuilten, N Waters, M Polonsky, A Renzaho
Vox sanguinis 106 (2), 137-143, 2014
112014
Rational: A randomised controlled feasibility trial comparing prophylactic immunoglobulin with antibiotics in patients with acquired hypogammaglobulinemia secondary to …
Z McQuilten, R Weinkove, P Crispin, A Degelia, C Dendle, M Gilbertson, ...
Lippincott Williams and Wilkins, 2021
22021
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy
ZK McQuilten, R Weinkove, LTP Thao, P Crispin, A Degelia, C Dendle, ...
Blood Advances 8 (7), 1787-1795, 2024
12024
Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND …
Z McQuilten, S Heritier, L Fox, V Fox, L Young, P Blombery, I Cunningham, ...
BMJ open 14 (1), e076246, 2024
12024
Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia-the Diaamond-Ava-First and …
Z McQuilten, LC Fox, V Fox, S Heritier, TJ Batt, P Blombery, J Curnow, ...
Blood 140 (Supplement 1), 2931-2932, 2022
12022
Understanding and meeting clinical platelet requirements: an analysis of indications and urgency of platelet use from the prospective utilisation of platelets and plasma (Puppy …
N Polizzotto, N Waters, M Comande, G Grigoriadis, M Borosak, D Jolley
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 94, 455-456, 2009
12009
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
S Carrillo De Albornoz, AM Higgins, D Petrie, A Irving, L Fanning, ...
Blood Advances, bloodadvances. 2023012047, 2024
2024
Protocol: Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the …
Z McQuilten, S Heritier, L Fox, V Fox, L Young, P Blombery, I Cunningham, ...
BMJ Open 14 (1), 2024
2024
Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry
A Nelson, PJ Ho, H Haysom, N Waters, C Wellard, M Chee, J Teo, ...
Internal Medicine Journal, 2023
2023
Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II …
EM Wood, KL Chai, J Reynolds, J Griffiths, B Beaton, J Callum, ...
Blood 142, 1295, 2023
2023
Tranexamic Acid to Prevent Bleeding in Patients with Hematologic Malignancies and Severe Thrombocytopenia (TREATT trial). a Randomized Placebo-Controlled Trial
LJ Estcourt, ZK McQuilten, P Bardy, M Cole-Sinclair, GP Collins, ...
Blood 142, 702, 2023
2023
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry
LC Fox, ZK McQuilten, F Firkin, V Fox, X Badoux, A Bajel, P Barbaro, ...
Best Practice & Research Clinical Haematology, 101516, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20